Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].

Gastroenterologia y hepatologia - 1 Jul 2014

Albillos Agustín, Luis Calleja José, Molina Esther, Planas Ramon, Romero-Gómez Manuel, Turnes Juan, Hernández-Guerra Manuel

Abstract excerpt

The first-line option in the treatment of patients with advanced fibrosis and cirrhosis due to genotype 1 hepatitis C virus is currently triple therapy with boceprevir/telaprevir and pegylated interferon-ribavirin. However, certain limitations could constitute a barrier to starting treatment or achieving sustained viral response in these patients. These limitations include the patient's or physician's perception...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypertension, Portal

Share to Medication Adherence

Share to Metabolic Syndrome

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Protease Inhibitors

Source

Identifiers

PMID: 25907434
DOI: 10.1016/S0210-5705(15)30003-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].PMID 25907434Read ↗

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.Semantic proximity Read ↗

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

[Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].Semantic proximity Read ↗

High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.Semantic proximity Read ↗

Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from RomaniaSemantic proximity Read ↗

[Difficult-to-treat patients with chronic hepatitis C].Semantic proximity Read ↗

A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 1 patients with cirrhosis.Semantic proximity Read ↗

[Advance in the management of the difficult-to-treat patients with chronic hepatitis C].Semantic proximity Read ↗

Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.